A team of researchers reports that they have provided details for a step-by-step plan for an international effort to create a digital twin of the human immune system. Their study “Building digital twins of the human immune system: toward a roadmap” appears in Nature Digital Medicine.
“This paper outlines a road map that the scientific community should take in building, developing, and applying a digital twin of the immune system,” said Tomas Helikar, PhD, a University of Nebraska-Lincoln biochemist who is one of 10 co-authors from six universities from around the world. Earlier this year, the NIH renewed a five-year $1.8 million grant for Helikar to continue his work in the area.
“This is an effort that will require the collaboration of computational biologists, immunologists, clinicians, mathematicians and computer scientists,” he added. “Trying to break down this complexity down into measurable and achievable steps has been a challenge. This paper is addressing that.”
“Digital twins, customized simulation models pioneered in industry, are beginning to be deployed in medicine and healthcare, with some major successes, for instance in cardiovascular diagnostics and in insulin pump control. Personalized computational models are also assisting in applications ranging from drug development to treatment optimization. More advanced medical digital twins will be essential to making precision medicine a reality,” write the investigators.
“Because the immune system plays an important role in such a wide range of diseases and health conditions, from fighting pathogens to autoimmune disorders, digital twins of the immune system will have an especially high impact. However, their development presents major challenges, stemming from the inherent complexity of the immune system and the difficulty of measuring many aspects of a patient’s immune state in vivo.
“This perspective outlines a roadmap for meeting these challenges and building a prototype of an immune digital twin. It is structured as a four-stage process that proceeds from a specification of a concrete use case to model constructions, personalization, and continued improvement.”
Precision medicine for broad range of diseases
A digital twin of the immune system would be a breakthrough that could offer precision medicine for a wide array of ailments, including cancer, autoimmune disease, and viral infections like COVID-19, according to the scientists.
Helikar’s involvement has been inspired in part by his 7-year-old son, who required a lung transplant as an infant. This has resulted in a life-long careful balancing of his immune system through powerful immunosuppression drugs to prevent organ rejection while keeping infections and other diseases at bay.
While the first step is to create a generic model that reflects common biological mechanisms, the eventual goal is to make virtual models at the individual level. That would enable doctors to deliver treatments precisely designed for the individual.
“The dream and goal are for it to be used for precision medicine at the level of an individual,” explained Helikar. “Importantly, we change over time. Our immune system is programmed, reprogrammed and tweaked over time. It develops from birth and as we get older, it continues developing, often in ways we don’t like. It becomes weaker, we have cancers, and our immune system is not keeping up. Our goal is to create digital twins that are not just specific to ourselves, but specific to that point in time–taking into consideration all of our past.”
The study’s authors of are part of an umbrella working group of about 200 scientists organized for multiscale modeling of viral pandemics. The inter-agency working group is led by Reinhard Laubenbacher, PhD, of the University of Florida and James Glazier, PhD, of Indiana University, both co-authors of the May 20 report. Since May, Helikar has been co-leading the working group with Glazier.
Other co-authors include Gary An, MD (University of Vermont), Anna Niakaris, PhD (Université Paris-Saclay), and Rahuman S. Malik Sheriff, PhD (European Bioinformatics Institute).
While the effort could take years and hundreds of millions of dollars, Hellikar believes it is achievable.
“I think we have enough data and technological advancements in terms of methods and software tools, that the first draft or first version of the virtual immune system could be built with data that already exists,” he said. “It may not be personalizable yet, but you could start with it as a working prototype.”
